Prefilled Syringes Market Valued at $13.1 Billion by 2030

The Prefilled Syringes Market is forecasted to increase from USD 7.1 billion in 2024 to USD 13.1 billion by 2030, growing at a CAGR of 10.8%. Prefilled syringes are valued for their convenience and precision in delivering single doses of medication, helping to reduce drug waste and extend product shelf life. Their rising adoption is driven by the growing prevalence of chronic illnesses, increased demand for effective drug delivery systems, and regulatory support for safer injection methods. These devices are commonly used for biologics, vaccines, and other therapeutic products, enhancing patient safety by minimizing errors and ensuring accurate dosing. The market's expansion is fueled by the increasing incidence of chronic diseases and the trend towards self-administration. However, challenges such as product recalls and competition from alternative drug delivery methods may hinder growth. The rising demand for biologics and biosimilars is a significant driver, with glass and single-chamber syringes expected to dominate the market. North America remains a key market due to its advanced healthcare infrastructure and strong demand for precise drug delivery solutions. Major players include BD, Gerresheimer AG, SCHOTT, and West Pharmaceutical Services.

Download PDF Brochure:

Prefilled Syringes Market Dynamics

Drivers

· Rising target disease population

· Rapid growth in generic products

· Rising adoption of self-medication and digitalization

· Affordable cost with increased efficiency of prefilled syringes

· Technological advancements

Restraints

· Dearth of prefilled syringes with integrated safety features

Opportunities

· Growing healthcare infrastructure across emerging markets

· Surge of biologics and biosimilars in biopharma industry

· Increasing adoption of wearable drug delivery technologies

Challenges

· Availability of cheaper alternatives

· Challenges associated with manufacturing of prefilled syringes

Key Market Players

Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (US), Baxter International Inc (US), Ompi (Italy), Catalent, Inc. (US), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), Elcam Medical (Israel), YPSOMED (Switzerland), Oval Medical Technologies (UK), SHL Medical AG (Switzerland), Terumo (Japan).

Request Sample Pages

North America accounted for the largest market share of the global prefilled syringes industry, by region in the forecast period.
The pre-filled syringe market is anticipated to be dominated by the North American region due to a number of factors, including an advanced healthcare infrastructure, a high prevalence of chronic diseases, and a focus on patient safety and technological innovation. Its dominant position in the market is also a result of the region’s well-established pharmaceutical industry and rising demand for practical and precise drug delivery solutions. Furthermore, continued R&D expenditures and favorable regulatory environments in North America contribute to the expansion and use of pre-filled syringes.

Recent Developments

· In October 2018, Becton, Dickinson and Company launched the BD Intevi 1mL two-step disposable autoinjector.

· In July 2020, Becton, Dickinson and Company entered into an partnership with Biomedical Advanced Research and Development Authority (BARDA) (US)

· In July 2018, Becton, Dickinson and Company acquired Teva Medical Inc. (US)

Content Source:

https://www.marketsandmarkets.com/PressReleases/prefilled-syringes.asp

https://www.marketsandmarkets.com/ResearchInsight/prefilled-syringes-market.asp

https://www.prnewswire.com/news-releases/prefilled-syringes-market-worth-8-6-billion-by-2025---exclusive-report-by-marketsandmarkets-301133829.html

Comments

Popular posts from this blog

Urology Devices Industry worth $48.6 billion by 2028

Bronchoscopy Market Size Worth USD 3.7 billion By 2027 | CAGR: 7.9%: MarketsandMarkets™

Healthcare Simulation Market worth $4.6 billion by 2028